243 related articles for article (PubMed ID: 16407832)
1. Genome-wide profiling of promoter methylation in human.
Hatada I; Fukasawa M; Kimura M; Morita S; Yamada K; Yoshikawa T; Yamanaka S; Endo C; Sakurada A; Sato M; Kondo T; Horii A; Ushijima T; Sasaki H
Oncogene; 2006 May; 25(21):3059-64. PubMed ID: 16407832
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
[TBL] [Abstract][Full Text] [Related]
3. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
5. HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes.
Shaknovich R; Figueroa ME; Melnick A
Methods Mol Biol; 2010; 632():191-201. PubMed ID: 20217579
[TBL] [Abstract][Full Text] [Related]
6. CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene.
Schroeder M; Mass MJ
Biochem Biophys Res Commun; 1997 Jun; 235(2):403-6. PubMed ID: 9199206
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
8. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma.
Tanaka R; Wang D; Morishita Y; Inadome Y; Minami Y; Iijima T; Fukai S; Goya T; Noguchi M
Cancer; 2005 Feb; 103(3):608-15. PubMed ID: 15612080
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
Murao K; Kubo Y; Ohtani N; Hara E; Arase S
Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
[TBL] [Abstract][Full Text] [Related]
10. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
[TBL] [Abstract][Full Text] [Related]
11. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
[TBL] [Abstract][Full Text] [Related]
12. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
13. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
14. Aberrant hypermethylation at the bcl-2 locus at 18q21 in human lung cancers.
Nagatake M; Osada H; Kondo M; Uchida K; Nishio M; Shimokata K; Takahashi T; Takahashi T
Cancer Res; 1996 Apr; 56(8):1886-91. PubMed ID: 8620509
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.
Tessema M; Willink R; Do K; Yu YY; Yu W; Machida EO; Brock M; Van Neste L; Stidley CA; Baylin SB; Belinsky SA
Cancer Res; 2008 Mar; 68(6):1707-14. PubMed ID: 18339850
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
19. A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies.
Yu L; Liu C; Bennett K; Wu YZ; Dai Z; Vandeusen J; Opavsky R; Raval A; Trikha P; Rodriguez B; Becknell B; Mao C; Lee S; Davuluri RV; Leone G; Van den Veyver IB; Caligiuri MA; Plass C
Genomics; 2004 Oct; 84(4):647-60. PubMed ID: 15475242
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation markers of surfactant proteins in lung cancer.
Lin Z; Thomas NJ; Bibikova M; Seifart C; Wang Y; Guo X; Wang G; Vollmer E; Goldmann T; Garcia EW; Zhou L; Fan JB; Floros J
Int J Oncol; 2007 Jul; 31(1):181-91. PubMed ID: 17549420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
